Introduction
Hypertriglyceridemia and hypercholesterolemia are frequently found in diabetic patients, particularly those with nephropahty (1). Both are thought to play some role in the high incidence of atherosclerosis in these patients. A similarity in pathogenesis between glomerular lesions due to hyperlipidemia and atherosclerotic lesions has been suggested (2). Strict control of hyperlipidemia in addition to glycemic control is important for atherosclerosis prevention in diabetic patients.
Although decreased albuminuria by lipid lowering drugs in hyperlipidemic diabetic patients over 3 months has been reported (3), it remains unclear whether or not lipid lowering drugs can be successful in preventing albuminuria in diabetic patients over a long period.
We analyzed apolipoprotein Al, B100 containing particles or remnant-like particles (RLP) reflecting chylomicron or VLDL remnants which are most likely to be atherogenic particles (4). These have been isolated by immunoaffinity columns prepared with monoclonal antibodies in NIDDM patients with hypercholesterolemia.
We also investigated the effects of pravastatin, a 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor class of CH-lowering drug (5) or bezafibrate, a leading member of the fibrate family which regulates both the cholesterol (CH) and triglyceride metabolisms (6). We examined the CH content of these particles and urinary albumin excretion in NIDDM patients with hypercholesterolemia over a four-year-period. Al containing particles (Apo Al-CH) and apolipoprotein B100 containing particles (Apo B100-CH) after administration of bezafibrate and pravastatin. noted in group A, but it was not significant.
As shown in Fig. 2 , significant reductions in triglyceride (44.6%), total-CH (18.9%) and Apo B100-CH (24.7%) occurred after administration of bezafibrate over 4 years. An increase in Apo Al-CH (11.0%) took place after administration of the drug. However, it was not significant. Significant reductions in total-CH (20.3%) and Apo B100-CH (26.6%) occurred after administration of pravastatin over 4 years.
As shown in Fig. 3 , a significant increase in apolipoprotein Al (10.9%) and significant decreases in RLP-CH (67.9%) and apolipoprotein B100 (19.8%) were also noted after administration of bezafibrate over a four-year period. A significant decrease in apolipoprotein B100 (23.4%) occurred after administration of pravastatin over 4 years.
As shown in Fig. 4 , systolic blood pressure, diastolic blood pressure, Cr and Alb-I remained almost unchanged Ischemic heart disease was, however, noted in each group (group A : 2.7%, group B : 2.9%) after 4 years. Both drugs induced nearly the same preventative effect on atherosclerosis in NIDDM patients. Pravastatin has been shown to decrease albuminuria in hyperlipidemic diabetic patients over a 3-month period (3). Glomerular lesions due to hyperlipidemia and atherosclerotic lesions have exhibited a similarity in pathogenesis (2). LDL stimulates mesangial fibronectin production, inducing extracellular matrix expansion (15). Pravastatin inhibits mesangial cell proliferation by means other than lipid-lowering (16). These drugs may ameliorate glomerular injury by not only reducing serum lipid levels, but also by inhibiting mesangial cell proliferation.
Urinary albumin excretion did not increase in either group over 48 months. HbA1c levels in our groups were almost the same as in the good HbA1c group (using intensive treatment, which slows the development of diabetic nephropathy) in DCCT (17). However, the age and systolic and diastolic blood pressure levels in our groups were significantly higher than in the DCCT group. Although systolic blood pressure elevation accelerates the development of diabetic nephropathy (18), urinary albumin excretion did not increase in either group over 48 months. Therefore, anti-lipid drugs appear to be useful in the preventive treatment of albuminuria.
In addition to controlling blood glucose and blood pressure, anti-lipid drugs may play a significant role in the prevention of deteriorated albuminuria in NIDDM patients.
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